Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1231-1235

  Maekawa, Ryuji ^a   Maki, Hideo ^a   Yoshida, Hiroshi ^a   Hojo, Kanji ^a   Tanaka, Hidekazu ^a   Wada, Tohru ^a   Uchida, Naomi ^a   Takeda, Yukihiro ^a   Kasai, Hisanori ^a   Okamoto, Hiroyuki ^a   Tsuzuki, Hiroshige ^a   Kambayashi, Yoshikazu ^a   Watanabe, Fumihiko ^a   Kawada, Kenji ^a   Toda, Ken Ichi ^b   Ohtani, Mitsuaki ^a   Sugita, Kenji ^a   Yoshioka, Takayuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON CARCINOMA; CORRELATION FUNCTION; DRUG EFFICACY; FEMALE; LIVER METASTASIS; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR BLOOD FLOW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR MATRIX; FEMALE; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS;

EID: 0033559205     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Yu, A. E., Herwitt, R. E., Connor, E. W., and Stetler-Stevenson, W. G. Matrix metalloproteinases: novel targets for directed cancer therapy. Drugs Aging, 11: 229-244, 1997.
2. Liotta, L. A., and Stetler-Stevenson, W. G. Metalloproteinases and cancer invasion. Semin. Cancer Biol., 1: 99-106, 1990.
3. MacDougall, J. R., and Matrisian, L. M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev., 14: 351-362, 1995.
4. Jiang, W. G., Puntis, M. C. A., and Hallett, M. B. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br. J. Surg., 81: 1576-1590, 1994.
5. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
6. Bicknell, R., and Harris, A. L. Mechanisms and therapeutic implications of angiogenesis. Curr. Opin. Oncol., 8: 60-65, 1996.
7. Gastl, G., Hermann, T., Steurer, M., Zmija, J., Gunsilius, E., Unger, C., and Klaft, A. Angiogenesis as a target for tumor treatment. Oncology, 54: 177-184, 1997.
8. Mousa, S., A. Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Fut, 23: 51-60, 1998.
9. Winder, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
10. Macchiarini, P., Fontanini, G., Hardin, M. J., Squartini, F., and Angeletti, C. A. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet, 340: 145-146, 1992.
11. Tanigawa, N., Amaya, H., Matsumura, M. Shimomatsuya, T., Horiuchi, T., Muraoka, R., and Iki, M. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res., 56: 2671-2676, 1996.
12. Tanigawa, N., Amaya, H., Matsumura, M., Lu, C., Kitaoka, A., Matsuyama, K., and Muraoka, R. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res., 57: 1043-1046, 1997.
13. Weinder, N., Carrol, P. R., Flax, J., Blumenfeld, W., and Folkman, J. Tumor angiogenesis correlates with metastasis in invasis prostatic carcinoma. Am. J. Pathol., 143: 401-409, 1993.
14. Brown, P. D., Bloxidge, R. E., Stuart, N. S. E., Gatter, K. C., and Carmichael, J. Association between expression of activated 72-kirodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J. Natl. Cancer Inst., 85: 574-578, 1993.
15. Pajouh, M. S., Nagle, R. B., Breathnach, R., Finch, J. S., Brawler M. K., and Bowden, G. T. Expression of metalloproteinase genes in human prostate cancer. J. Cancer Clin. Oncol., 117: 144-150, 1991.
16. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C., and Chambon, P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond.), 348: 699-704, 1990.
17. Murrer, D., Breathnach, R., Engelman, A., Millon, R., Bronner, G., Flesch H., Dumont, P., Eber, M., and Abecassis, J. Expression of collagenase related metalloproteinase genes in human lung or head and neck tumors. Int. J. Cancer, 48: 550-556. 1991.
18. Compo, E., Merino, M. J., Tavassoli, F. A., Charonis, A. S., Stetler-Stevenson, W. G., and Liotta, L. A. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serious tumors of the ovary. Am. J. Surg. Pathol., 16: 500-507, 1991.
19. Gress, T. M., Muller-Pillasch, F., Lerch, M. M., Freiss, H., Buchler, M., and Alder, G. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int. J. Cancer, 62: 407-413, 1995.
20. Woolley, D. E. Collagenolytic mechanisms in tumor cell invasion. J. Cancer Clin. Oncol., 23: 583-589, 1984.
21. Monteagudo, C., Merino, M. J., San-Juan, J., Liotta, L. A., and Stetler-Stevenson, W. G. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am. J. Pathol., 136: 585-592, 1990.
22. Brown, P. D., Bloxodge, R., E., Stuart, N. S. A., Gatter, K. C., and Carmichael, J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J. Natl. Cancer Inst., 85: 574-578, 1993.
23. Rao, J. S., Steck, P. A., Mohanam, S., Stetler-Stevenson, W. G., and Liotta, L. A. Elevated levels of Mw 92,000 type IV collagenase in human brain tumors. Cancer Res., 53: 2208-2211, 1993.
24. Brown, P. Matrix metalloproteinase inhibitors: a new class of anticancer agent. Curr. Opin. Invest. Drugs. 2: 617-626, 1993.
25. Beckett, R. P., Davidson, A., H., Drummond, A., H., Huxley, P., and Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discov. Today, 1: 16-26, 1996.
26. Talbot, D. C., and Brown, P. D. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur. J. Cancer, 32A: 2528-2533, 1996.
27. Denis, L. J., and Verweij, J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs. 15: 175-185, 1997.
28. Rasmussen, H. S., and McCann, P. P. Matrix metalloproteinase inhibitors as a novel anticancer strategy: a review with special focus on Batimastat and Marimastat. Pharmacol. Ther., 75: 69-75, 1997.
29. White, A. D., Bocan, T. M. A., Boxer, P. A., Peterson, J. T., and Dehrier, D. Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors. Curr. Pharm. Des., 3: 45-58, 1997.
30. Tamura, Y., Watanabe, H., Nakatani, T., Yasui, K., Fuji, M., Komurasaki, T., Tsuzuki, H., Maekawa, R., Yoshioka, T., Kawada, K., Sugita, K., and Ohtani, M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem., 41: 640-649, 1998.
31. Toda, K., Tsujioka, K., Maruguchi, Y., Ishii, K., Miyachi, Y., Kuribayasi, K., and Imamura, S. Establishment and characterization of a tumorigenic murine vascular endothelial cell line (F-2). Cancer Res., 50: 5526-5530, 1990.
32. Dickens, J. P., Crimmin, M. J., and Beckett, R. P. PCT patent Application WO9402447, 1994.
33. Ward, R. V., Hembry, R. M., Reynolds, J. J., and Murphy, G. The purification of tissue inhibitor of metalloproteinase-2 from its 72 kDa progelatinase complex. Biochem. J., 278: 179-187, 1991.
34. Tanaka, H., Hojo, K., Yoshida, H., Yoshioka, T., and Sugita, K. Molecular cloning and expression of the mouse 105-kDa gelatinase cDNA. Biochem. Biophys. Res. Commun. 190: 732-740, 1993.
35. Itoh, T. Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., and Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 58: 1048-1051, 1998.
36. Uchida, N., Kasai, H., Takeda, Y., Maekawa, R., Sugita, K., and Yoshioka, T. Augmented antitumor activity in combination chemotherapy of Nedaplatin with Etoposide. Anticancer Res., 18: 247-252, 1998.
37. Dunnett, C. W. New tables for multiple comparisons with a control. Biometrics, 20: 482-491, 1964.
38. Babine R. E., and Bender, S. L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev., 97: 1359-1472, 1997.
39. Nemunaitis, J., Poole, C., Primrose, J., Rosemurgy, A., Malfetano, J., Brown, P., Berrington, H., Cornish, A., Lynch, K., Rasmussen, H., Kerr, D., Cox, D., and Millar, A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res., 4: 1101-1109, 1998.
40. Wojtowicz-Praga, S., Torri, J., Johnson, M., Steen, V., Marshall, J., Ness, E., Dickson R., Sale M., Rasmussen, H. S., Chiodo, T. A., and Hawkins M. J. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol., 16: 2150-2156, 1998.